BackCytokinetics Overview
Cytokinetics Inc

Cytokinetics Target Price

See Cytokinetics's analyst price targets ($110) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$56.16

Average Target Price

$110.5096.8% upside

6 analysts in the last 4 months

High: $113 | Low: $104

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-14UBSAshwani Verma$10485.2% upsideOpen
2026-10-08RBC CapitalLeonid Timashev$113101.2% upsideOpen
2026-08-13Barclays$11095.9% upsideOpen
2026-08-10Truist FinancialSrikripa Devarakonda$11299.4% upsideOpen
2026-08-07RBC CapitalLeonid Timashev$11299.4% upsideOpen
2026-08-07NeedhamSerge Belanger$11299.4% upsideOpen
2026-07-07RBC CapitalLeonid Timashev$117108.3% upsideOpen
2026-06-29UBSAshwani Verma$115104.8% upsideOpen
2026-06-24Mizuho Securities$118110.1% upsideOpen
2026-06-17RBC CapitalLeonid Timashev$119111.9% upsideOpen
2026-05-11H.C. Wainwright$140149.3% upsideOpen
2026-05-06Stifel Nicolaus$10892.3% upsideOpen
2026-05-06UBS$119111.9% upsideOpen
2026-05-06Morgan Stanley$10383.4% upsideOpen
2026-05-05Truist FinancialSrikripa Devarakonda$10688.7% upsideOpen
2026-04-10Wells Fargo$9569.2% upsideOpen
2026-03-10Robert W. BairdRoanna Ruiz$8449.6% upsideOpen
2026-03-06UBSAshwani Verma$6922.9% upsideOpen
2026-02-20RBC Capital$10179.8% upsideOpen
2026-02-03Truist FinancialSrikripa Devarakonda$9263.8% upsideOpen
2026-01-09JefferiesAkash Tewari$9060.3% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$9060.3% upsideOpen
2025-12-22Truist FinancialSrikripa Devarakonda$8449.6% upsideOpen
2025-12-22Morgan Stanley$7126.4% upsideOpen
2025-12-22Leerink PartnersRoanna Ruiz$8347.8% upsideOpen
2025-12-22RBC Capital$9569.2% upsideOpen
2025-12-22NeedhamSerge Belanger$8449.6% upsideOpen
2025-12-22Goldman Sachs$9976.3% upsideOpen
2025-12-22H.C. WainwrightJoseph Pantginis$136142.2% upsideOpen
2025-12-22Barclays$8754.9% upsideOpen
2025-12-18Goldman Sachs$9569.2% upsideOpen
2025-12-01UBSAshwani Verma$618.6% upsideOpen
2025-10-06BarclaysGena Wang$8246% upsideOpen
2025-09-03Evercore ISICory Kasimov$8042.5% upsideOpen
2025-09-03BarclaysGena Wang$7126.4% upsideOpen
2025-09-02Stifel NicolausJames Condulis$9670.9% upsideOpen
2025-04-24BarclaysGena Wang$552.1% downsideOpen
2025-03-07Morgan Stanley$6719.3% upsideOpen
2024-10-17H.C. WainwrightJoseph Pantginis$120113.7% upsideOpen
2024-09-03Goldman SachsPaul Choi$606.8% upsideOpen
2024-06-10Piper SandlerYasmeen Rahimi$10790.5% upsideOpen
2024-06-04B.Riley FinancialMayank Mamtani$9263.8% upsideOpen
2024-05-28JMP SecuritiesJason Butler$7838.9% upsideOpen
2024-05-23H.C. WainwrightJoseph Pantginis$9060.3% upsideOpen
2024-05-23NeedhamSerge Belanger$7228.2% upsideOpen
2024-05-23JefferiesAkash Tewari$8551.4% upsideOpen
2024-05-23BarclaysCarter Gould$9569.2% upsideOpen
2024-05-09OppenheimerJustin Kim$10688.7% upsideOpen
2024-05-09JMP SecuritiesJason Butler$10688.7% upsideOpen
2024-04-05Mizuho SecuritiesSalim Syed$9976.3% upsideOpen

Cytokinetics (CYTK) FAQ

Cytokinetics (CYTK) currently reports a target price of $110. Use the charts on this page to explore Cytokinetics's target price history and peer comparisons.

Analysts' average 12-month price target for Cytokinetics is $110, about 96.8% upside from the current share price of $56.16. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $110, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cytokinetics, and consider following CYTK for alerts when major investors trade the stock.

Cytokinetics is classified in the Healthcare sector. On target price, it currently shows $110. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTK with unrelated industries.